Investment bank Raymond James lowers Insulet's price target to $216 due to recent market volatility. Despite a downturn, the medical device company's strong Q1 performance and the anticipated success of its innovative Omnipod 5 system hold promise for long-term growth. Insulet's ongoing battle with market competition and its robust financial health position it as a potential key player in the diabetes management market. Read more

BrightSpring Health Services' officer liquidates 35,000 shares worth $2.06M, part of the $15M secondary share offering. Despite the transaction, remaining a substantial healthcare industry player with an $11.13B market cap, the company retains investor attention with its 'B' Zacks Momentum Style Score. Read more